Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Pulmonary Fibrosis Biomarker Market Outlook from 2024 to 2034

Sales of pulmonary fibrosis biomarkers are expected to accelerate at a CAGR of 4.4% from 2024 to 2034. The pulmonary fibrosis biomarker market is projected to increase from US$ 4,353.0 million in 2024 to US$ 6,538.4 million by 2034. The market was valued at US$ 4,149.0 million in 2023.

Increased developments in pulmonary fibrosis biomarkers, making it easier to find and validate new biomarkers and integrate them into clinical practice, contribute to the market expansion of pulmonary fibrosis biomarkers. The market is witnessing growth due to the application of bioinformatics tools and the development of high-throughput screening techniques.

Attributes Details
Pulmonary Fibrosis Biomarker Market Size (2024) US$ 4,353.0 million
Expected Market Size (2034) US$ 6,538.4 million
CAGR (2024 to 2034) 4.4%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Forces Behind the Pulmonary Fibrosis Biomarker Market Growth

  • The pulmonary fibrosis biomarker market is expanding because regulatory frameworks support the development and approval of biomarkers for the diagnosis, prognosis, and treatment monitoring of pulmonary fibrosis.
  • Age-related illnesses like pulmonary fibrosis are prevalent as the world's population ages, which contributes to the demand for pulmonary fibrosis biomarkers that help to manage the disease in older populations.
  • Patient organizations' advocacy efforts stimulate the demand for biomarkers, which are increasing public awareness of pulmonary fibrosis and pushing for better monitoring and diagnostic technologies.
  • Continuous investigation into new biomarkers and their correlation with pulmonary fibrosis broadens the array of choices and propels market expansion of pulmonary fibrosis biomarkers.

Limiting Factors in the Pulmonary Fibrosis Biomarker Market

  • The high expense of biomarker discovery, development, and validation and the unpredictability of reimbursement rules hamper investment in research and development.
  • Though great progress has been made, much remains to be understood about the underlying mechanisms of pulmonary fibrosis. This incomplete knowledge makes it challenging to find and validate trustworthy biomarkers.
  • To accurately identify and track pulmonary fibrosis, many of the biomarkers presently studied lack the necessary specificity and sensitivity, resulting in false positives or negatives and lowering their therapeutic usefulness.
  • Biomarker validation and certification comply with strict regulations, which impedes the release of new biomarkers. This impedes the market growth.
Attributes Details
Pulmonary Fibrosis Biomarker Market Value (2018) US$ 3,330.6 million
Estimated Market Value for 2023 US$ 4,149.0 million
CAGR from 2019 to 2023 4.5%
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Growth Avenues in the Pulmonary Fibrosis Biomarker Market

  • The prevalence of pulmonary fibrosis is rising worldwide. It is a progressive illness with a high death rate. Aging populations, changing lifestyles, and environmental concerns are the primary contributors to this trend.
  • Regulatory bodies increasingly acknowledge the significance of biomarkers in medication development and clinical practice. There are opportunities for pulmonary fibrosis biomarker market expansion due to initiatives to expedite the regulatory approval procedure for biomarker-based treatments and diagnostics.
  • In addition to diagnostic businesses, the demand for pulmonary fibrosis biomarkers includes pharmaceutical companies, biotechnology companies, contract research organizations, and academic institutions. This varied ecosystem aids innovation and market expansion of pulmonary fibrosis biomarkers.

Comparative View of Adjacent Pulmonary Fibrosis Biomarker Market

The progressive pulmonary fibrosis (PPF) treatment market and the EPO biomarker market have both been studied in comparison to the pulmonary fibrosis biomarker market. The data depicted in the tables below highlights the projected CAGRs, key trends, and opportunities in these markets.

Pulmonary Fibrosis Biomarker Market:

Attributes Pulmonary Fibrosis Biomarker Market
Value-based CAGR (2024 to 2034) 4.4%
Growth Factor The increasing focus on precision medicine propels the demand for novel biomarker assays in diagnosing pulmonary fibrosis.
Market Trend Treatment response and the advancements of pulmonary fibrosis are monitored with minimally invasive methods because of liquid biopsy-based biomarkers.
Market Restraint The lack of consistent validation hinders the wide adoption of pulmonary fibrosis biomarkers.

Progressive Pulmonary Fibrosis (PPF) Treatment Market:

Attributes Progressive Pulmonary Fibrosis (PPF) Treatment Market
Value-based CAGR (2024 to 2034) 7.5%
Growth Factor The field of PPF treatment is changing as a result of new anti-fibrotic medications.
Market Trend Personalized PPF therapy is becoming more popular with the use of precision medical techniques.
Market Restraint Patients find it difficult to afford the high cost of new PPF therapies.

EPO Biomarkers Market:

Attributes EPO Biomarkers Market
Value-based CAGR (2024 to 2034) 5.3%
Growth Factor A growing emphasis on the management of anemia in chronic illnesses fuels the demand for EPO biomarkers.
Market Trend EPO biomarker testing to detect doping is becoming more prevalent in sports medicine.
Market Restraint The absence of agreement on standardized EPO biomarker assays inhibits the wide adoption of the test.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Outlook

Consumer Preference for Imaging Tests

Top Type Segment Share (2024)
Imaging Tests 50.8%
  • The preference for imaging tests continues to rise because imaging facilities are available in different healthcare settings, accelerating the market growth.
  • The capacity of imaging tests to offer real-time information and enable prompt treatment decisions that encourage their increased adoption of pulmonary fibrosis biomarkers.
  • Imaging tests are widely accepted and dominate the market since they are less expensive than invasive alternatives.
  • In contrast to invasive procedures like lung biopsies, imaging tests provide non-invasive assessment, lowering patient discomfort and risk.

Use of Pulmonary Fibrosis Biomarkers for Early Identification and Monitoring of Idiopathic Pulmonary Fibrosis (IPF)

Top Indication Segment Share (2024)
Idiopathic pulmonary fibrosis (IPF) 42.6%
  • Due to the aging population, one of the main risk factors for IPF, there is an increasing demand for pulmonary fibrosis biomarkers for early identification and monitoring.
  • Diagnostic innovations that identify IDF at an early stage, allowing for timely management and mitigation of disease development, are aided by market expansion.
  • The fact that there are few choices for treating idiopathic pulmonary fibrosis highlights the pulmonary fibrosis biomarker demand to enable tailored treatments and enhance patient outcomes.

Wider Adoption of Pulmonary Fibrosis Biomarkers in Hospitals

Top End User Segment Share (2024)
Hospitals 33.4%
  • The integration of hospitals with the current healthcare system encourages the widespread adoption of pulmonary fibrosis biomarker testing.
  • Hospitals frequently act as referral hubs, streamlining diagnostic processes and boosting their market share in the pulmonary fibrosis biomarker sector.
  • Hospitals are positioned as major pulmonary fibrosis biomarker market growth catalysts because of the established trust that affects patient compliance with biomarker testing.

Country-wise Analysis

This section examines the pulmonary fibrosis biomarker markets in several significant economies, such as the United States, Spain, the United Kingdom, India, and China. It also explores different factors that influence pulmonary fibrosis biomarker demand, adoption, and sales across these countries.

Country CAGR (2024 to 2034)
China 11.4%
India 6.9%
Spain 8.2%
United States 3.5%
Germany 5.5%

Pulmonary Fibrosis Biomarker Industry in China

  • China's leadership in the pulmonary fibrosis biomarker market results from the cooperation between Chinese research institutions and multinational pharmaceutical companies, which promotes a cross-cultural exchange of expertise.
  • China is at the pinnacle of pulmonary fibrosis research due to government initiatives and funding in precision medicine programs that push the adoption of cutting-edge biomarker technology.
  • China's quick advances greatly aid the discovery and validation of novel pulmonary fibrosis biomarkers in machine learning and artificial intelligence.

Pulmonary Fibrosis Biomarker Industry in India

  • The demand for pulmonary fibrosis biomarkers is receiving greater attention in India due to a rise in the prevalence of respiratory disorders and increased knowledge among medical professionals.
  • Governmental programs that encourage domestic research and development enhance India's ability to provide advanced biomarkers adapted to the particular requirements of the regional pulmonary fibrosis patient group.
  • India's economical biomarker research projects support the global endeavor to lower costs and increase the adoption of pulmonary fibrosis diagnostics.

Pulmonary Fibrosis Biomarker Industry in Spain

  • An increasing network of research collaborations encouraging a collaborative approach to biomarker development improves Spain's pulmonary fibrosis biomarker market.
  • Due to its participation in international clinical trials, Spain is positioned to play a key role in the global quest for credible pulmonary fibrosis biomarkers.
  • Spain's stance in the pulmonary fibrosis biomarker landscape is improved by changing reimbursement policies and providing more financing for respiratory research programs.

Pulmonary Fibrosis Biomarker Industry in the United States

  • Significant clinical trials and a strong healthcare infrastructure influence the shifting landscape of pulmonary fibrosis biomarker discovery in the United States.
  • The demand for pulmonary fibrosis biomarkers is increasing in the United States due to increased awareness among patients and medical professionals.
  • The United States is positioned as a major market influencer owing to regulatory initiatives like expedited approval processes that accelerate the use of innovative biomarkers.

Pulmonary Fibrosis Biomarker Industry in the United Kingdom

  • Patient organizations and strong advocacy groups shape research priorities and ensure that pulmonary fibrosis biomarkers are relevant in the United Kingdom's healthcare system.
  • The United Kingdom is committed to providing patient-friendly diagnostic solutions, reflected in the collaborative efforts between academia and industry to develop noninvasive biomarkers.
  • The adoption of advanced pulmonary fibrosis diagnostic methods in the United Kingdom has accelerated the National Health Service's (NHS) integration of biomarkers into ordinary clinical practice.

Competitive Landscape

Key pulmonary fibrosis biomarker manufacturers significantly shape the sector's competitive landscape. Known for its dedication to innovation, Biogen welcomes Veracyte, which is one of the significant pulmonary fibrosis biomarker providers, emphasizing cutting-edge diagnostic solutions.

Galapagos NV offers its advantages to the market, while Genentech, a Roche company, adds its pharmaceutical knowledge. Biocartis and Myriad Genetics are essential in pulmonary fibrosis biomarkers since they offer specific solutions.

These key pulmonary fibrosis biomarker vendors work together to enhance research and development, which supports the market's general expansion and development for pulmonary fibrosis biomarkers. Their combined efforts highlight the pulmonary fibrosis biomarker industry's dynamic nature as it continues to tackle the difficulties related to pulmonary fibrosis.

Latest Advancements

  • To provide Oklahomans with the newest diagnostic and therapeutic equipment, O.U. Health, a comprehensive academic health system, and Siemens Healthineers, a leader in medical technology, announced a strategic 10-year value partnership in December 2023.
  • Thermo Fisher Scientific and AstraZeneca collaborated in January 2023 to create a companion diagnostic test for Tagrisso based on solid tissue and blood. With its global presence, Thermo Fisher Scientific can service a wide range of clients and take advantage of expansion prospects worldwide.
  • A deal to buy all of the outstanding shares of Curiosity Diagnostics from Scope Fluidics, S.A., was announced by Bio-Rad Laboratories, Inc. in August 2022. The deal could be worth up to US$ 170 million, with roughly US$ 100 million going toward cash and another US$ 70 million coming from future milestone payments.
  • Biogen Inc. agreed to pay a total of US$ 900 million in September 2022 to settle allegations that it gave doctors payments to persuade them to prescribe Biogen drugs, which resulted in the doctors making false claims with Medicare and Medicaid.

Prominent Pulmonary Fibrosis Biomarker Vendors

  • Biogen
  • Veracyte
  • Genentech (Roche)
  • Galapagos NV
  • Biocartis
  • Myriad Genetics

Market Segmentation

By Test:

  • Blood Tests
    • C-reactive Protein Testing Kits
    • Antibody Testing Kits
      • Antinuclear Antibodies (ANA) Test
      • Anti-CCP antibody testing
    • ESR Tests and CBC
  • Imaging Tests
    • X-rays Scans
    • HRCT Scans
  • Lung Biopsy

By Indication:

  • Idiopathic pulmonary fibrosis (IPF)
  • Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
  • Drug-induced pulmonary fibrosis
  • COVID-19-related pulmonary fibrosis
  • Pneumoconiosis
  • Sarcoidosis
  • Others

By End User:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers

By Region:

  • North America
  • Latin America
  • East Asia
  • South Asia and Pacific
  • Western Europe
  • Eastern Europe
  • Middle East Asia

Frequently Asked Questions

How Big Was the Pulmonary Fibrosis Biomarker Market in 2023?

The pulmonary fibrosis biomarker was valued at US$ 4,149.0 million in 2023.

What is the Projected Value of the Pulmonary Fibrosis Biomarker Market by 2034?

The demand for pulmonary fibrosis biomarkers is set to reach a valuation of US$ 6,538.4 million by the end of 2034.

What is the Growth Potential of the Pulmonary Fibrosis Biomarker Market?

The market is anticipated to expand at a 4.4% CAGR through 2034.

Which Test Type Segment Contributes to the Pulmonary Fibrosis Biomarker Market?

The imaging tests segment is expected to acquire a market share of 44.9% in 2024.

What is the Estimated Size of the Pulmonary Fibrosis Biomarker Market in 2024?

Sales of pulmonary fibrosis biomarkers are estimated to be valued at US$ 4,353.0 million in 2024.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Area Development/Innovation Trends

4. Value Added Insights

    4.1. Product Assessment

        4.1.1. Product Adoption Analysis

        4.1.2. Product USP's/Features Analysis

        4.1.3. Recent Product Launches and Innovations

    4.2. Regulatory Guidelines

        4.2.1. Legal Requirements and Frameworks in the USA

        4.2.2. Legal Requirements and Frameworks in Europe

        4.2.3. Legal Requirements and Frameworks in Japan

        4.2.4. Legal Requirements and Frameworks in China

        4.2.5. Legal Requirements and Frameworks in India

        4.2.6. Legal Requirements and Frameworks in Australia

    4.3. Disease Epidemiology, By Key Countries

        4.3.1. Prevalence of Population, By Country

        4.3.2. Gender and Age-Specific Cases

        4.3.3. Severity-Specific Cases

        4.3.4. Diagnosed Prevalence Cases

    4.4. Pipeline Assessment

        4.4.1. Comprehensive Assessment by End Users

        4.4.2. By Disease Indication

        4.4.3. Emerging Novel trends

        4.4.4. Late-stage Pipeline Assessment

    4.5. Porter’s Analysis

    4.6. Regional PESTEL Analysis

    4.7. Value Chain Analysis

    4.8. Unmet Needs Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. Global Life Expectancy Outlook

        5.1.3. R & D Funding By Region

        5.1.4. R & D Funding By Country

        5.1.5. R & D Spending, By Pharma Players

        5.1.6. Top 25 Companies by R & D Spend in 2023

        5.1.7. Parent Market Outlook

    5.2. Forecast Factors - Relevance and Impact

        5.2.1. Regulatory Initiatives and Incentives

        5.2.2. Technological Advancements in Trial Design

        5.2.3. Patient-Centric Approaches and Advocacy

        5.2.4. Global Collaborations and Partnerships

        5.2.5. Increased Focus on Rare Diseases

        5.2.6. Inclusive Trial Designs for Diverse Populations

        5.2.7. Ethical Considerations and Informed Consent

        5.2.8. Advancements in Pediatric Precision Medicine

        5.2.9. Integration of Real-World Evidence (RWE)

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034

    6.1. Historical Market Value (US$ Million) Analysis, 2018 to 2024

    6.2. Current and Future Market Value (US$ Million) Projections, 2024 to 2034

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) By Test Type, 2018 to 2023

    7.3. Current and Future Market Size (US$ Million) and Forecast ty Test Type, 2024 to 2034

        7.3.1. Blood Tests:

            7.3.1.1. C-Reactive Protein Testing Kits

            7.3.1.2. Antibody Testing Kits

                7.3.1.2.1. Antinuclear Antibodies (ANA) Test

                7.3.1.2.2. Anti-CCP antibody testing

            7.3.1.3. ESR Tests and CBC

        7.3.2. Imaging Tests

            7.3.2.1. X-rays Scans

            7.3.2.2. HRCT Scans

        7.3.3. Lung Biopsy

    7.4. Market Attractiveness Analysis by Region

8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis by Indication, 2018 to 2023

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Indication, 2024 to 2034

        8.3.1. Idiopathic pulmonary fibrosis (IPF)

        8.3.2. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)

        8.3.3. Drug-induced pulmonary fibrosis

        8.3.4. COVID-19-related pulmonary fibrosis

        8.3.5. Pneumoconiosis

        8.3.6. Sarcoidosis

        8.3.7. Others

    8.4. Market Attractiveness Analysis By Test

9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) By End User, 2018 to 2023

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast by End User, 2024 to 2034

        9.3.1. Hospitals

        9.3.2. Specialty Clinics

        9.3.3. Diagnostic Laboratories

        9.3.4. Diagnostic Imaging Centers

    9.4. Market Attractiveness Analysis by End User

10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2023

    10.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2024 to 2034

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. East Asia

        10.3.4. South Asia and Pacific

        10.3.5. Western Europe

        10.3.6. Eastern Europe

        10.3.7. Middle East and Africa

    10.4. Market Attractiveness Analysis by Region

11. North America Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    11.1. Introduction

    11.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    11.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        11.3.1.  By Country

            11.3.1.1. USA

            11.3.1.2. Canada

            11.3.1.3. Mexico

        11.3.2. By Test Type

        11.3.3. By Indication

        11.3.4. By End User

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Test Type

        11.4.3. By Indication

        11.4.4. By End User

    11.5. Market Trends

    11.6. Drivers and Restraints - Impact Analysis

    11.7. Country Level Analysis and Forecast

        11.7.1. USA Market Analysis

            11.7.1.1.  Introduction

            11.7.1.2. Market Analysis and Forecast by Market Taxonomy

                11.7.1.2.1. By Test Type

                11.7.1.2.2. By Indication

                11.7.1.2.3. By End User

        11.7.2. Canada Market Analysis

            11.7.2.1. Introduction

            11.7.2.2. Market Analysis and Forecast by Market Taxonomy

                11.7.2.2.1. By Test Type

                11.7.2.2.2. By Indication

                11.7.2.2.3. By End User

        11.7.3. Mexico Market Analysis

            11.7.3.1. Introduction

            11.7.3.2. Market Analysis and Forecast by Market Taxonomy

                11.7.3.2.1. By Test Type

                11.7.3.2.2. By Indication

                11.7.3.2.3. By End User

12. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    12.1. Introduction

    12.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Chile

            12.3.1.3. Rest of Latin America

        12.3.2. By Test Type

        12.3.3. By Indication

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Test Type

        12.4.3. By Indication

        12.4.4. By End User

    12.5. Market Trends

    12.6. Drivers and Restraints - Impact Analysis

    12.7. Country Level Analysis and Forecast

        12.7.1. Brazil Market Analysis

            12.7.1.1. Introduction

            12.7.1.2. Market Analysis and Forecast by Market Taxonomy

                12.7.1.2.1. By Test Type

                12.7.1.2.2. By Indication

                12.7.1.2.3. By End User

        12.7.2. Chile Market Analysis

            12.7.2.1. Introduction

            12.7.2.2. Market Analysis and Forecast by Market Taxonomy

                12.7.2.2.1. By Test Type

                12.7.2.2.2. By Indication

                12.7.2.2.3. By End User

13. East Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    13.1. Introduction

    13.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        13.3.1.  By Country

            13.3.1.1. China

            13.3.1.2. Japan

            13.3.1.3. South Korea

        13.3.2. By Test Type

        13.3.3. By Indication

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Test Type

        13.4.3. By Indication

        13.4.4. By End User

    13.5. Market Trends

    13.6. Drivers and Restraints - Impact Analysis

    13.7. Country Level Analysis and Forecast

        13.7.1. China Market Analysis

            13.7.1.1. Introduction

            13.7.1.2. Market Analysis and Forecast by Market Taxonomy

                13.7.1.2.1. By Test Type

                13.7.1.2.2. By Indication

                13.7.1.2.3. By End User

        13.7.2. Japan Market Analysis

            13.7.2.1. Introduction

            13.7.2.2. Market Analysis and Forecast by Market Taxonomy

                13.7.2.2.1. By Test Type

                13.7.2.2.2. By Indication

                13.7.2.2.3. By End User

        13.7.3. South Korea Market Analysis

            13.7.3.1. Introduction

            13.7.3.2. Market Analysis and Forecast by Market Taxonomy

                13.7.3.2.1. By Test Type

                13.7.3.2.2. By Indication

                13.7.3.2.3. By End User

14. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    14.1. Introduction

    14.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        14.3.1.  By Country

            14.3.1.1. India

            14.3.1.2. ASEAN Countries

            14.3.1.3. Australia and New Zealand

            14.3.1.4. Rest of South Asia and Pacific

        14.3.2. By Test Type

        14.3.3. By Indication

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Test Type

        14.4.3. By Indication

        14.4.4. By End User

    14.5. Market Trends

    14.6. Drivers and Restraints - Impact Analysis

    14.7. Country Level Analysis and Forecast

        14.7.1. India Market Analysis

            14.7.1.1. Introduction

            14.7.1.2. Market Analysis and Forecast by Market Taxonomy

                14.7.1.2.1. By Test Type

                14.7.1.2.2. By Indication

                14.7.1.2.3. By End User

        14.7.2. ASEAN Countries Market Analysis

            14.7.2.1. Introduction

            14.7.2.2. Market Analysis and Forecast by Market Taxonomy

                14.7.2.2.1. By Test Type

                14.7.2.2.2. By Indication

                14.7.2.2.3. By End User

        14.7.3. Australia and New Zealand Market Analysis

            14.7.3.1. Introduction

            14.7.3.2. Market Analysis and Forecast by Market Taxonomy

                14.7.3.2.1. By Test Type

                14.7.3.2.2. By Indication

                14.7.3.2.3. By End User

15. Western Europe Market 2018 to 2023and Forecast 2024 to 2034

    15.1. Introduction

    15.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        15.3.1.  By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. UK

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Nordic Countries

            15.3.1.8. Rest of Western Europe

        15.3.2. By Test Type

        15.3.3. By Indication

        15.3.4. By End User

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Test Type

        15.4.3. By Indication

        15.4.4. By End User

    15.5. Market Trends

    15.6. Drivers and Restraints - Impact Analysis

    15.7. Country Level Analysis and Forecast

        15.7.1. Germany Market Analysis

            15.7.1.1. Introduction

            15.7.1.2. Market Analysis and Forecast by Market Taxonomy

                15.7.1.2.1. By Test Type

                15.7.1.2.2. By Indication

                15.7.1.2.3. By End User

        15.7.2. France Market Analysis

            15.7.2.1. Introduction

            15.7.2.2. Market Analysis and Forecast by Market Taxonomy

                15.7.2.2.1. By Test Type

                15.7.2.2.2. By Indication

                15.7.2.2.3. By End User

        15.7.3. Spain Market Analysis

            15.7.3.1. Introduction

            15.7.3.2. Market Analysis and Forecast by Market Taxonomy

                15.7.3.2.1. By Test Type

                15.7.3.2.2. By Indication

                15.7.3.2.3. By End User

        15.7.4. Italy Market Analysis

            15.7.4.1. Introduction

            15.7.4.2. Market Analysis and Forecast by Market Taxonomy

                15.7.4.2.1. By Test Type

                15.7.4.2.2. By Indication

                15.7.4.2.3. By End User

        15.7.5. BENELUX Market Analysis

            15.7.5.1. Introduction

            15.7.5.2. Market Analysis and Forecast by Market Taxonomy

                15.7.5.2.1. By Test Type

                15.7.5.2.2. By Indication

                15.7.5.2.3. By End User

        15.7.6. Nordic Countries Market Analysis

            15.7.6.1. Introduction

            15.7.6.2. Market Analysis and Forecast by Market Taxonomy

                15.7.6.2.1. By Test Type

                15.7.6.2.2. By Indication

                15.7.6.2.3. By End User

        15.7.7. United Kingdom Market Analysis

            15.7.7.1. Introduction

            15.7.7.2. Market Analysis and Forecast by Market Taxonomy

                15.7.7.2.1. By Test Type

                15.7.7.2.2. By Indication

                15.7.7.2.3. By End User

16. Eastern Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    16.1. Introduction

    16.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        16.3.1.  By Country

            16.3.1.1. Russia

            16.3.1.2. Hungary

            16.3.1.3. Poland

            16.3.1.4. Rest of Eastern Europe

        16.3.2. By Test Type

        16.3.3. By Indication

        16.3.4. By End User

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Test Type

        16.4.3. By Indication

        16.4.4. By End User

    16.5. Market Trends

    16.6. Drivers and Restraints - Impact Analysis

    16.7. Country Level Analysis and Forecast

        16.7.1. Russia Market Analysis

            16.7.1.1. Introduction

            16.7.1.2. Market Analysis and Forecast by Market Taxonomy

                16.7.1.2.1. By Test Type

                16.7.1.2.2. By Indication

                16.7.1.2.3. By End User

        16.7.2. Hungary Market Analysis

            16.7.2.1. Introduction

            16.7.2.2. Market Analysis and Forecast by Market Taxonomy

                16.7.2.2.1. By Test Type

                16.7.2.2.2. By Indication

                16.7.2.2.3. By End User

        16.7.3. Poland Market Analysis

            16.7.3.1. Introduction

            16.7.3.2. Market Analysis and Forecast by Market Taxonomy

                16.7.3.2.1. By Test Type

                16.7.3.2.2. By Indication

                16.7.3.2.3. By End User

17. Middle East and Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034

    17.1. Introduction

    17.2. Historical Market Size (US$ Million) Analysis by Market Taxonomy, 2018 to 2023

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2024 to 2034

        17.3.1.  By Country

            17.3.1.1. Saudi Arabia

            17.3.1.2. Türkiye

            17.3.1.3. South Africa

            17.3.1.4. Other African Union

            17.3.1.5. Rest of MEA

        17.3.2. By Test Type

        17.3.3. By Indication

        17.3.4. By End User

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Test Type

        17.4.3. By Indication

        17.4.4. By End User

    17.5. Market Trends

    17.6. Drivers and Restraints - Impact Analysis

    17.7. Country Level Analysis and Forecast

        17.7.1. Saudi Arabia Market Analysis

            17.7.1.1. Introduction

            17.7.1.2. Market Analysis and Forecast by Market Taxonomy

                17.7.1.2.1. By Test Type

                17.7.1.2.2. By Indication

                17.7.1.2.3. By End User

        17.7.2. Türkiye Market Analysis

            17.7.2.1. Introduction

            17.7.2.2. Market Analysis and Forecast by Market Taxonomy

                17.7.2.2.1. By Test Type

                17.7.2.2.2. By Indication

                17.7.2.2.3. By End User

        17.7.3. South Africa Market Analysis

            17.7.3.1. Introduction

            17.7.3.2. Market Analysis and Forecast by Market Taxonomy

                17.7.3.2.1. By Test Type

                17.7.3.2.2. By Indication

                17.7.3.2.3. By End User

        17.7.4. Other African Union Market Analysis

            17.7.4.1. Introduction

            17.7.4.2. Market Analysis and Forecast by Market Taxonomy

                17.7.4.2.1. By Test Type

                17.7.4.2.2. By Indication

                17.7.4.2.3. By End User

18. Market Structure Analysis

    18.1. Market Share Analysis of Top Sponsors

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Branding and Promotional Strategies by Key Stakeholders

    19.4. Key Competitive Deep Dive

        19.4.1. Roche Diagnostics

            19.4.1.1. Overview

            19.4.1.2. Services Portfolio

            19.4.1.3. Key Financials

            19.4.1.4. SWOT Analysis

            19.4.1.5. Key Developments

            19.4.1.6. Sales Footprint

            19.4.1.7. Strategy Overview

        19.4.2. Siemens Healthineers

        19.4.3. Bio-Rad Laboratories

        19.4.4. Eagle Biosciences, Inc.

        19.4.5. Biogenix Inc. Pvt. Ltd.

        19.4.6. Diagnostic Automation/Cortez Diagnostics Inc.

        19.4.7. BioSupply Ltd.

        19.4.8. Bio-Diagnostics Ltd.

        19.4.9. MERIDIAN BIOSCIENCE

        19.4.10. Weldon Biotech, Inc.

        19.4.11. Getein Biotech, Inc.

        19.4.12. Creative Diagnostics

        19.4.13. Beijing Strong Biotechnologies, Inc.

        19.4.14. Merck KGaA

        19.4.15. CTK Biotech, Inc.

        19.4.16. Personal Diagnostics

        19.4.17. Thermo Fisher Scientific Inc.

20. Assumptions and Acronyms Used

21. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 01: Global Market Value (US$ Million) Analysis and Forecast, by Test

Table 03: Global Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 04: Global Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 05: Global Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Region

Table 06: North America Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 07: North America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 08: North America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 09: North America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 10: Latin America Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 11: Latin America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 12: Latin America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 13: Latin America Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 14: East Asia Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 15: East Asia Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 16: East Asia Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 17: East Asia Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 18: South Asia and Pacific Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 19: South Asia and Pacific Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 20: South Asia and Pacific Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 21: South Asia and Pacific Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 22: Western Europe Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 23: Western Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 24: Western Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 25: Western Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 26: Eastern Europe Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 27: Eastern Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 28: Eastern Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 29: Eastern Europe Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User

Table 30: Middle East and Africa Market Value (US$ Million) Analysis 2018 to 2023 and Forecast 2024 to 2034, by Country

Table 31: Middle East and Africa Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Test

Table 32: Middle East and Africa Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by Indication

Table 33: Middle East and Africa Market Value (US$ Million) Analysis and Forecast 2018 to 2034, by End User
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) Analysis, 2018 to 2023

Figure 2: Global Market Forecast and Y-o-Y Growth, 2024 to 2034

Figure 3: Global Market Absolute $ Opportunity (US$ Million) Analysis, 2023 to 2034

Figure 4: Global Market Value Share (%) Analysis 2023 and 2034, by Test

Figure 5: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Test

Figure 6: Global Market Attractiveness Analysis 2024 to 2034, by Test

Figure 7: Global Market Value Share (%) Analysis 2023 and 2034, by Indication

Figure 8: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Indication

Figure 9: Global Market Attractiveness Analysis 2024 to 2034, by Indication

Figure 10: Global Market Value Share (%) Analysis 2023 and 2034, by End User

Figure 11: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by End User

Figure 12: Global Market Attractiveness Analysis 2024 to 2034, by End User

Figure 13: Global Market Value Share (%) Analysis 2023 and 2034, by Region

Figure 14: Global Market Y-o-Y Growth (%) Analysis 2024 to 2034, by Region

Figure 15: Global Market Attractiveness Analysis 2024 to 2034, by Region

Figure 16: North America Market Value (US$ Million) Analysis, 2018 to 2023

Figure 17: North America Market Value (US$ Million) Forecast, 2024 to 2034

Figure 18: North America Market Value Share, by Test (2024 E)

Figure 19: North America Market Value Share, by Indication (2024 E)

Figure 20: North America Market Value Share, by End User (2024 E)

Figure 21: North America Market Value Share, by Country (2024 E)

Figure 22: North America Market Attractiveness Analysis by Test, 2024 to 2034

Figure 23: North America Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 24: North America Market Attractiveness Analysis by End User, 2024 to 2034

Figure 25: North America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 26: USA Market Value Proportion Analysis, 2023

Figure 27: Global Vs. USA Growth Comparison, 2024 to 2034

Figure 28: USA Market Share Analysis (%) by Test, 2024 to 2034

Figure 29: USA Market Share Analysis (%) by Indication, 2024 to 2034

Figure 30: USA Market Share Analysis (%) by End User, 2024 to 2034

Figure 31: Canada Market Value Proportion Analysis, 2023

Figure 32: Global Vs. Canada. Growth Comparison, 2024 to 2034

Figure 33: Canada Market Share Analysis (%) by Test, 2024 and 2034

Figure 34: Canada Market Share Analysis (%) by Indication, 2024 to 2034

Figure 35: Canada Market Share Analysis (%) by End User, 2024 to 2034

Figure 36: Mexico Market Value Proportion Analysis, 2023

Figure 37: Global Vs. Mexico Growth Comparison, 2024 to 2034

Figure 38: Mexico Market Share Analysis (%) by Test, 2024 to 2034

Figure 39: Mexico Market Share Analysis (%) by Indication, 2024 to 2034

Figure 40: Mexico Market Share Analysis (%) by End User, 2024 to 2034

Figure 41: Latin America Market Value (US$ Million) Analysis, 2018 to 2023

Figure 42: Latin America Market Value (US$ Million) Forecast, 2024 to 2034

Figure 43: Latin America Market Value Share, by Test (2024 E)

Figure 44: Latin America Market Value Share, by Indication (2024 E)

Figure 45: Latin America Market Value Share, by End User (2024 E)

Figure 46: Latin America Market Value Share, by Country (2024 E)

Figure 47: Latin America Market Attractiveness Analysis by Test, 2024 to 2034

Figure 48: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 49: Latin America Market Attractiveness Analysis by End User, 2024 to 2034

Figure 50: Latin America Market Attractiveness Analysis by Country, 2024 to 2034

Figure 51: Brazil Market Value Proportion Analysis, 2023

Figure 52: Global Vs. Brazil. Growth Comparison, 2024 to 2034

Figure 53: Brazil Market Share Analysis (%) by Test, 2024 to 2034

Figure 54: Brazil Market Share Analysis (%) by Indication, 2024 to 2034

Figure 55: Brazil Market Share Analysis (%) by End User, 2024 to 2034

Figure 56: Chile Market Value Proportion Analysis, 2023

Figure 57: Global Vs. Chile Growth Comparison, 2024 to 2034

Figure 58: Chile Market Share Analysis (%) by Test, 2024 to 2034

Figure 59: Chile Market Share Analysis (%) by Indication, 2024 to 2034

Figure 60: Chile Market Share Analysis (%) by End User, 2024 to 2034

Figure 61: East Asia Market Value (US$ Million) Analysis, 2018 to 2023

Figure 62: East Asia Market Value (US$ Million) Forecast, 2024 to 2034

Figure 63: East Asia Market Value Share, by Test (2024 E)

Figure 64: East Asia Market Value Share, by Indication (2024 E)

Figure 65: East Asia Market Value Share, by End User (2024 E)

Figure 66: East Asia Market Value Share, by Country (2024 E)

Figure 67: East Asia Market Attractiveness Analysis by Test, 2024 to 2034

Figure 68: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 69: East Asia Market Attractiveness Analysis by End User, 2024 to 2034

Figure 70: East Asia Market Attractiveness Analysis by Country, 2024 to 2034

Figure 71: China Market Value Proportion Analysis, 2023

Figure 72: Global Vs. China Growth Comparison, 2024 to 2034

Figure 73: China Market Share Analysis (%) by Test, 2024 to 2034

Figure 74: China Market Share Analysis (%) by Indication, 2024 to 2034

Figure 75: China Market Share Analysis (%) by End User, 2024 to 2034

Figure 76: Japan Market Value Proportion Analysis, 2023

Figure 77: Global Vs. Japan Growth Comparison, 2024 to 2034

Figure 78: Japan Market Share Analysis (%) by Test, 2024 to 2034

Figure 79: Japan Market Share Analysis (%) by Indication, 2024 to 2034

Figure 80: Japan Market Share Analysis (%) by End User, 2024 to 2034

Figure 81: South Korea Market Value Proportion Analysis, 2023

Figure 82: Global Vs South Korea Growth Comparison, 2024 to 2034

Figure 83: South Korea Market Share Analysis (%) by Test, 2024 to 2034

Figure 84: South Korea Market Share Analysis (%) by Indication, 2023 to 2034

Figure 85: South Korea Market Share Analysis (%) by End User, 2024 to 2034

Figure 86: South Asia and Pacific Market Value (US$ Million) Analysis, 2018 to 2023

Figure 87: South Asia and Pacific Market Value (US$ Million) Forecast, 2024 to 2034

Figure 88: South Asia and Pacific Market Value Share, by Test (2024 E)

Figure 89: South Asia and Pacific Market Value Share, by Indication (2024E)

Figure 90: South Asia and Pacific Market Value Share, by End User (2024 E)

Figure 91: South Asia and Pacific Market Value Share, by Country (2024 E)

Figure 92: South Asia and Pacific Market Attractiveness Analysis by Test, 2024 to 2034

Figure 93: South Asia and Pacific Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 94: South Asia and Pacific Market Attractiveness Analysis by End User, 2024 to 2034

Figure 95: South Asia and Pacific Market Attractiveness Analysis by Country, 2024 to 2034

Figure 96: India Market Value Proportion Analysis, 2023

Figure 97: Global Vs. India Growth Comparison, 2024 to 2034

Figure 98: India Market Share Analysis (%) by Test, 2024 to 2034

Figure 99: India Market Share Analysis (%) by Indication, 2024 to 2034

Figure 100: India Market Share Analysis (%) by End User, 2024 to 2034

Figure 101: ASEAN Countries Market Value Proportion Analysis, 2023

Figure 102: Global Vs. ASEAN Countries Growth Comparison, 2024 to 2034

Figure 103: ASEAN Countries Market Share Analysis (%) by Test, 2024 to 2034

Figure 104: ASEAN Countries Market Share Analysis (%) by Indication, 2024 to 2034

Figure 105: ASEAN Countries Market Share Analysis (%) by End User, 2024 to 2034

Figure 106: Australia and New Zealand Market Value Proportion Analysis, 2023

Figure 107: Global Vs. Australia and New Zealand Growth Comparison, 2024 to 2034

Figure 108: Australia and New Zealand Market Share Analysis (%) by Test, 2023 and2034

Figure 109: Australia and New Zealand Market Share Analysis (%) by Indication, 2024 to 2034

Figure 110: Australia and New Zealand Market Share Analysis (%) by End User, 2023 and2034

Figure 111: Western Europe Market Value (US$ Million) Analysis, 2018 to 2023

Figure 112: Western Europe Market Value (US$ Million) Forecast, 2024 to 2034

Figure 113: Western Europe Market Value Share, by Test (2024 E)

Figure 114: Western Europe Market Value Share, by Indication (2024 E)

Figure 115: Western Europe Market Value Share, by End User (2024 E)

Figure 116: Western Europe Market Value Share, by Country (2024 E)

Figure 117: Western Europe Market Attractiveness Analysis by Test, 2024 to 2034

Figure 118: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 119: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034

Figure 120: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 121: UK Market Value Proportion Analysis, 2023

Figure 122: Global Vs. UK Growth Comparison, 2024 to 2034

Figure 123: UK Market Share Analysis (%) by Test, 2024 to 2034

Figure 124: UK Market Share Analysis (%) by Indication, 2024 to 2034

Figure 125: UK Market Share Analysis (%) by End User, 2024 to 2034

Figure 126: Germany Market Value Proportion Analysis, 2023

Figure 127: Global Vs. Germany Growth Comparison, 2024 to 2034

Figure 128: Germany Market Share Analysis (%) by Test, 2024 to 2034

Figure 129: Germany Market Share Analysis (%) by Indication, 2024 to 2034

Figure 130: Germany Market Share Analysis (%) by End User, 2024 to 2034

Figure 131: Italy Market Value Proportion Analysis, 2023

Figure 132: Global Vs. Italy Growth Comparison, 2024 to 2034

Figure 133: Italy Market Share Analysis (%) by Test, 2024 to 2034

Figure 134: Italy Market Share Analysis (%) by Indication, 2024 to 2034

Figure 135: Italy Market Share Analysis (%) by End User, 2024 to 2034

Figure 136: France Market Value Proportion Analysis, 2023

Figure 137: Global Vs France Growth Comparison, 2024 to 2034

Figure 138: France Market Share Analysis (%) by Test, 2024 to 2034

Figure 139: France Market Share Analysis (%) by Indication, 2024 to 2034

Figure 140: France Market Share Analysis (%) by End User, 2024 to 2034

Figure 141: Spain Market Value Proportion Analysis, 2023

Figure 142: Global Vs Spain Growth Comparison, 2024 to 2034

Figure 143: Spain Market Share Analysis (%) by Test, 2024 to 2034

Figure 144: Spain Market Share Analysis (%) by Indication, 2024 to 2034

Figure 145: Spain Market Share Analysis (%) by End User, 2024 to 2034

Figure 146: Nordic Countries Market Value Proportion Analysis, 2023

Figure 147: Global Vs Nordic Countries Growth Comparison, 2024 to 2034

Figure 148: Nordic Countries Market Share Analysis (%) by Test, 2024 to 2034

Figure 149: Nordic Countries Market Share Analysis (%) by Indication, 2024 to 2034

Figure 150: Nordic Countries Market Share Analysis (%) by End User, 2024 to 2034

Figure 151: BENELUX Market Value Proportion Analysis, 2023

Figure 152: Global Vs BENELUX Growth Comparison, 2024 to 2034

Figure 153: BENELUX Market Share Analysis (%) by Test, 2024 to 2034

Figure 154: BENELUX Market Share Analysis (%) by Indication, 2024 to 2034

Figure 155: BENELUX Market Share Analysis (%) by End User, 2024 to 2034

Figure 156: Eastern Europe Market Value (US$ Million) Analysis, 2018 to 2023

Figure 157: Eastern Europe Market Value (US$ Million) Forecast, 2024 to 2034

Figure 158: Eastern Europe Market Value Share, by Test (2024 E)

Figure 159: Eastern Europe Market Value Share, by Indication (2024 E)

Figure 160: Eastern Europe Market Value Share, by End User (2024 E)

Figure 161: Eastern Europe Market Value Share, by Country (2024 E)

Figure 162: Eastern Europe Market Attractiveness Analysis by Test, 2024 to 2034

Figure 163: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 164: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034

Figure 165: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034

Figure 166: Russia Market Value Proportion Analysis, 2023

Figure 167: Global Vs. Russia Growth Comparison, 2024 to 2034

Figure 168: Russia Market Share Analysis (%) by Test, 2024 to 2034

Figure 169: Russia Market Share Analysis (%) by Indication, 2024 to 2034

Figure 170: Russia Market Share Analysis (%) by End User, 2024 to 2034

Figure 171: Hungary Market Value Proportion Analysis, 2023

Figure 172: Global Vs Hungary Growth Comparison, 2024 to 2034

Figure 173: Hungary Market Share Analysis (%) by Test, 2024 to 2034

Figure 174: Hungary Market Share Analysis (%) by Indication, 2024 to 2034

Figure 175: Hungary Market Share Analysis (%) by End User, 2024 to 2034

Figure 176: Poland Market Value Proportion Analysis, 2023

Figure 177: Global Vs Poland Growth Comparison, 2024 to 2034

Figure 178: Poland Market Share Analysis (%) by Test, 2024 to 2034

Figure 179: Poland Market Share Analysis (%) by Indication, 2024 to 2034

Figure 180: Poland Market Share Analysis (%) by End User, 2024 to 2034

Figure 181: Middle East and Africa Market Value (US$ Million) Analysis, 2018 to 2023

Figure 182: Middle East and Africa Market Value (US$ Million) Forecast, 2024 to 2034

Figure 183: Middle East and Africa Market Value Share, by Test (2024 E)

Figure 184: Middle East and Africa Market Value Share, by Indication (2024E)

Figure 185: Middle East and Africa Market Value Share, by End User (2024 E)

Figure 186: Middle East and Africa Market Value Share, by Country (2024 E)

Figure 187: Middle East and Africa Market Attractiveness Analysis by Test, 2024 to 2034

Figure 188: Middle East and Africa Market Attractiveness Analysis by Indication, 2024 to 2034

Figure 189: Middle East and Africa Market Attractiveness Analysis by End User, 2024 to 2034

Figure 190: Middle East and Africa Market Attractiveness Analysis by Country, 2024 to 2034

Figure 191: Saudi Arabia Market Value Proportion Analysis, 2023

Figure 192: Global Vs Saudi Arabia Growth Comparison, 2024 to 2034

Figure 193: Saudi Arabia Market Share Analysis (%) by Test, 2024 to 2034

Figure 194: Saudi Arabia Market Share Analysis (%) by Indication, 2023 and2034

Figure 195: Saudi Arabia Market Share Analysis (%) by End User, 2024 to 2034

Figure 196: Türkiye Market Value Proportion Analysis, 2023

Figure 197: Global Vs. Türkiye Growth Comparison, 2024 to 2034

Figure 198: Türkiye Market Share Analysis (%) by Test, 2024 to 2034

Figure 199: Türkiye Market Share Analysis (%) by Indication, 2024 to 2034

Figure 200: Türkiye Market Share Analysis (%) by End User, 2024 to 2034

Figure 201: South Africa Market Value Proportion Analysis, 2023

Figure 202: Global Vs. South Africa Growth Comparison, 2024 to 2034

Figure 203: South Africa Market Share Analysis (%) by Test, 2024 to 2034

Figure 204: South Africa Market Share Analysis (%) by Indication, 2023 and2034

Figure 205: South Africa Market Share Analysis (%) by End User, 2024 to 2034

Figure 206: Other African Union Market Value Proportion Analysis, 2023

Figure 207: Global Vs Other African Union Growth Comparison, 2024 to 2034

Figure 208: Other African Union Market Share Analysis (%) by Test, 2024 to 2034

Figure 209: Other African Union Market Share Analysis (%) by Indication, 2024 to 2034

Figure 210: Other African Union Market Share Analysis (%) by End User, 2024 to 2034

Recommendations

Healthcare

Progressive Pulmonary Fibrosis (PPF) Treatment Market

Published : January 2023

Healthcare

EPO Biomarkers Market

Published : November 2022

Explore Healthcare Insights

View Reports

Pulmonary Fibrosis Biomarker Market